Trial dates have been set for the first four bellwether trials for blood thinner Xarelto, by Judge Eldon Fallon in multidistrict litigation docket MDL 2592 in the Eastern District of Louisiana.
Bellwether cases are designed to provide plaintiffs and their attorneys with a perspective on how the juries will react to the testimony provided and the evidence presented. More than 2,800 cases have been filed against the manufacturers of Xarelto:
- Janssen Research & Development LLC F/K/A Johnson and Johnson Pharmaceutical Research and Development LLC
- Janssen Ortho LLC
- Janssen Pharmaceuticals Inc. F/K/A Janssen Pharmaceutica Inc. F/K/A Ortho-Mcneil-Janssen Pharmaceuticals Inc.
- Johnson & Johnson Company Bayer Healthcare Pharmaceuticals Inc.
- Bayer Pharma Ag
- Bayer Corporation
- Bayer Healthcare LLC
- Bayer Healthcare Ag
- Bayer Ag
The first two of the bellwether cases were taken from a pool of 40 cases, and will be tried in 2017. The cases have been scheduled for trial on February 6, March 13, April 24 and May 30.
Many dangerous side effects
The drug is prescribed for atrial fibrillation (AFIB), deep vein thrombosis (DVT) and pulmonary embolism (PE). However, it causes brain/cerebral hemorrhage, death, gastrointestinal bleeding, heart attack, kidney bleeding, nosebleeds, rectal bleeding, respiratory failure, hemorrhagic and ischemic strokes, vaginal or uterine bleeding, and other internal bleeding.
The drug was approved by the FDA in 2011. So many lawsuits have filed that the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into the MDL in Louisiana. Meanwhile, many additional cases have been consolidated in the Philadephia Court Of Common Pleas.